The present study was designed to investigate the effect of pharmacological inhibition of endocannabinoid degradation on behavioural actions of the dopamine D 2 /D 3 receptor agonist quinpirole in male C57Bl/6J mice. In addition, we studied the effects of endocannabinoid degradation inhibition on both cocaineinduced psychomotor activation and behavioural sensitization. We analysed the effects of inhibition of the two main endocannabinoid degradation enzymes : fatty acid amide hydrolase (FAAH), using inhibitor URB597 (1 mg/kg) ; monoacylglycerol lipase (MAGL), using inhibitor URB602 (10 mg/kg). Administration of quinpirole (1 mg/kg) caused a temporal biphasic response characterized by a first phase of immobility (0-50 min), followed by enhanced locomotion (next 70 min) that was associated with the introduction of stereotyped behaviours (stereotyped jumping and rearing). Pretreatment with both endocannabinoid degradation inhibitors did not affect the hypoactivity actions of quinpirole. However, this pretreatment resulted in a marked decrease in quinpirole-induced locomotion and stereotyped behaviours. Administration of FAAH or MAGL inhibitors did not attenuate the acute effects of cocaine. Furthermore, these inhibitors did not impair the acquisition of cocaine-induced behavioural sensitization or the expression of cocaine-induced conditioned locomotion. Only MAGL inhibition attenuated the expression of an already acquired cocaine-induced behavioural sensitization. These results suggest that pharmacological inhibition of endocannabinoid degradation might exert a negative feedback on D 2 /D 3 receptor-mediated hyperactivity. This finding might be relevant for therapeutic approaches for either psychomotor disorders (dyskinesia, corea) or disorganized behaviours associated with dopaminemediated hyperactivity.
Introduction
The endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are retrograde messengers that regulate a variety of brain functions through stimulation of cannabinoid receptors type 1 and 2 (CB 1 and CB 2 ; Placzek et al. 2008 ; Wang & Ueda, 2008) . The CB 1 receptor is highly expressed on axon terminals of glutamatergic and c-aminobutyric acid (GABA)ergic projecting neurons, through which the endogenous cannabinoid system controls neurotransmitter release and synaptic plasticity (Adermark & Lovinger, 2007 ; Adermark et al. 2009 ; Gerdeman & Lovinger, 2001 ; Piomelli, 2003) . The endocannabinoid system (ECS) is mainly involved in motor, motivational, emotional and cognitive processes (Giuffrida et al. 1999 (Giuffrida et al. , 2004 Luchicchi et al. 2010 ; Rasmussen et al. 2009 ; Rodriguez de Fonseca et al. 1998 ; Solinas et al. 2007 ). In addition, the ECS regulates dopamine-mediated behaviours (Rodriguez de Fonseca et al. 2001 ). This role is related to its anatomical presence in basal ganglia circuits (Martin et al. 2008 ; Rodriguez de Fonseca et al. 1998 Solinas et al. 2008) .
Due to the presence of the ECS in brain dopaminergic circuits, much work has been performed to clarify its role in brain reward processes (Gardner, 2005) . For instance, pharmacological modulation of the ECS appears to regulate dopamine-mediated rewarding effects of alcohol, cannabis, opioids and psychostimulants (Colombo et al. 2005 ; de Vries et al. 2001 ; Ledent et al. 1999 ; Maldonado & Rodriguez de Fonseca, 2002 ; Scherma et al. 2008) . However, less work has been performed regarding behavioural consequences of endocannabinoid signalling modulation in motor control. Some evidence suggests that regulation of psychomotor output might depend on the interaction between the endocannabinoid and the dopaminergic systems in both the basal ganglia and the mesolimbic reward system (Giuffrida & Piomelli, 2000 ; Glass et al. 1997) .
Analysis of the role of the ECS in dopaminemediated behaviours suggests that endocannabinoids exert a complex regulatory role in both dopaminereleasing and dopamine receptor-expressing neurons. For instance, activation of the CB 1 receptor induces dopamine release in rodents and humans (Bossong et al. 2009 ; Ng Cheong Ton et al. 1988 ; O'Neill et al. 2009 ). This effect is thought to be mediated by the reinforcing properties of natural cannabinoids (Gardner, 2005) . Conversely, activation of dopamine D 2 /D 3 receptors stimulates production of the endocannabinoid AEA in the dorsal striatum (Giuffrida et al. 1999) . In this situation, the ECS would be acting as an inhibitory feedback mechanism that counteracts the dopamineinduced facilitation of motor activity (Beltramo et al. 2000) . Supporting this hypothesis, previous reports show that the CB 1 receptor agonist WIN 55,212-2 is able to ameliorate dyskinesias (Ferrer et al. 2003) . Conversely, the CB 1 receptor antagonist SR141716A aggravates the stereotypies induced by pharmacological over-activation of dopamine receptors (Ferrer et al. 2007) . Moreover, desensitization of CB 1 receptors induced by D9-tetrahydrocannabinol administration facilitates dopamine-mediated behaviours (Gorriti et al. 1999 (Gorriti et al. , 2005 .
Although the role of dopamine D 2 /D 3 receptors as activators of endocannabinoid release is well known (Giuffrida et al. 1999) , the effects of psychostimulants on the activation of the ECS are much less understood.
Among psychostimulants, cocaine is a monoamine reuptake inhibitor that interferes with the uptake of dopamine, noradrenaline and serotonin (Ritz et al. 1990) . Cocaine also induces an augmented motor response after repeated administration (sensitization ; Blanco et al. 2012a, b) . Acute cocaine administration increases AEA levels in the striatum (Arnold, 2005) . This effect is mediated by dopaminergic D 2 -like receptors (Arnold, 2005) . However, as in the case of dopamine D 2 /D 3 receptor agonists, there is no clear evidence that the increase of endocannabinoids induced by cocaine also acts as an inhibitory feedback signal for cocaine-induced stimulation. It is important to note that the effects of cocaine, including reinforcing effects, can be mediated by non-dopaminergic neurons through interactions with other neurotransmitter systems, such as the serotoninergic system (Hnasko et al. 2007) .
From the studies described above, we can hypothesize that endocannabinoids generated by dopamine D 2 /D 3 receptor activation serve as counter-regulatory signals that limit behavioural over-activation. To confirm this hypothesis, we performed studies with inhibitors of endocannabinoid degradation. AEA and 2-AG are generated by cells on demand through stimulus-dependent cleavage of membrane phospholipid precursor and undergo rapid biological deactivation after release (di Marzo et al. 1994 ; Stella et al. 1997) . Both AEA and 2-AG are degraded and eliminated through enzymatic hydrolysis by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (Cravatt et al. 1996 (Cravatt et al. , 2001 ). Blockage of this degradation will result in enhanced availability of endocannabinoids, which may counteract quinpirole-induced locomotion/stereotypy and cocaine-induced sensitization. Thus, the main goals of the present study were as follows : (a) to characterize locomotor activity and stereotypic behaviours induced by the dopamine D 2 /D 3 receptor agonist quinpirole in a mouse model ; (b) to evaluate the effects of FAAH and MAGL inhibition on quinpirole-induced behaviours ; (c) to assess the effects of FAAH and MAGL inhibition on horizontal locomotion, conditioned locomotion and behavioural sensitization induced by cocaine.
Method

Animals
C57B1/6J adult male mice (Charles River, Spain) were maintained in controlled housing conditions (12 h light/dark cycle, lights on 08 : 00 hours ; temperature : 20¡2 xC ; humidity : 40¡5 %) with food and water Cocaine hydrochloride (Sigma-Aldrich, Spain) was dissolved in a sterile saline solution and administered i.p. at doses of 10 or 20 mg/kg. All of the drugs were injected in a volume of 1 ml/kg.
Apparatus and general procedures
Animals were handled and habituated to injection procedures once per day for 5 d. All of the experiments were carried out between 08 : 00 and 20 : 00 hours. Each day, the animals were acclimatized to the experimental room for 30 min. Performance in the open field (OF) was recorded by a computer-based video tracking system (Smart v2.5 1 ; Panlab, Spain). Stereotyped behaviours were directly observed by placing the animals in transparent glass observational cylinders (OCs). The maximum light intensity in the centre of the OF and inside the OC was 100 lux. All of the apparatuses were cleaned with a 70 % ethanol solution.
Open field
Four OFs (50r50r50 cm ; Panlab) with grey backgrounds were used. Animals were placed in the centre of each arena and their behaviour was recorded for 30 or 120 min. Horizontal locomotion was measured as the total distance travelled (cm). The immobility variable was evaluated as the total time of immobility (s) using a detection filter (detection range less than 10 cm/s). Because analysis of locomotion and time spent in the centre of the OF is considered an index of anxiety in cannabinoid studies (Long et al. 2010 ; Thiemann et al. 2009 ), we also registered the distance travelled in periphery and centre area. The centre of the OF was defined as a square of 30r30 cm. A mouse was considered to be in the central area when its four paws were in it.
Observational cylinders
Quantification of stereotyped activity was performed by direct observation of the animals after they were placed in the glass transparent OCs (60 cm heightr 12 cm diameter). Eight cylinders were attached to the original base of the OF in the perimeter of the arena. Clean bedding material was added after each animal test. Animals were injected with Veh or QNP and/or the inhibitors of endocannabinoid degradation and placed in the cylinders. Evaluation of stereotyped behaviours (such as jumping, rearing and grooming) was performed by trained observers blind to the experimental conditions. Quantification was performed at 10 min time intervals for a total time of 120 min post-injection.
Behavioural procedures
We performed a total of five experiments. In expt 1, we evaluated the effect of QNP administration on locomotion/immobility behaviour in the OF. In expt 2, we analysed stereotyped behaviours in the OC. In expt 3, we assessed the effects of FAAH and MAGL inhibitors on anxiety, habituation, locomotion activity and stereotyped behaviours in the OF and OC. In expt 4, we analysed the effects of FAAH and MAGL inhibitors on QNP-induced locomotion and stereotyped behaviours in the OF and OC. Finally, we evaluated the effects of FAAH and MAGL inhibitors in acute/repeated cocaine administration, conditioned locomotion and behavioural sensitization in the OF (expt 5).
Evaluation of locomotion and stereotyped behaviours after administration of QNP and/or inhibitors of FAAH/MAGL in the OF and OC Animals were injected with Veh or different single doses of QNP (expt 1 and expt 2), URB597 or URB602 (expt 3) or were co-administered QNP+URB597 or QNP+URB602 (expt 4). When drugs were coadministered, URB597 and URB602 were injected 30 min before QNP.
Evaluation of FAAH/MAGL inhibitors on acute/ repeated cocaine administration, conditioned locomotion and behavioural sensitization in the OF Animals received a single i.p. injection of Veh, cocaine, URB597, URB602, URB597+cocaine or URB602+ cocaine in the different phases of the experiment (expt 5). Briefly, mice were exposed to acute or repeated cocaine administration (20 mg/kg) for five consecutive days. One half of the animals were treated with cocaine, cocaine+URB597 or cocaine+URB602. The other half of the animals were treated with Veh, URB597 or URB602. After the 5 d, mice rested in their home cages without drugs for another 5 d. Twentyfour hours later, we evaluated the conditioned locomotion response after administration of Veh, URB597 or URB602. On the last day, we tested the behavioural sensitization by injection of a prime dose of cocaine (10 mg/kg), cocaine (10 mg/kg)+URB597 or cocaine (10 mg/kg)+URB602. Using two other groups of animals, we also evaluated the effects of acute administration of URB597 and URB602 on an already acquired conditioned locomotion and cocaine sensitization response. During all of these phases, the animals were evaluated in the OF immediately after the drug or Veh injections to measure the distance travelled over 30 min. Conditioned locomotion and behavioural sensitization protocols used in this study are based on Pavlovian conditioning. Classical Pavlovian conditioning is a basic process of associative learning that allows an animal to predict and adapt to future events based on previous experience. Conditional learning involves the association of a neutral stimulus with an unconditional stimulus (UCS) that elicits an unconditional response (UCR). After repeated pairing, the neutral stimulus becomes a conditional stimulus (CS) that induces a conditional response (CR) similar to the original UCR. In our study, the psychostimulant cocaine (UCS) produces an increased locomotor response (UCR). Repeated pairing of drug administration (daily cocaine injections as UCS) with a specific context (OF as CS) typically leads to an enhanced locomotor response (conditioned locomotion as CR) when mice are re-exposed without cocaine in the OF. In addition, this conditioned motor-stimulant response is exponentially increased by a single injection of a prime dose of cocaine (behavioural sensitization).
Statistical analysis
Results were expressed as the mean¡S.E.M. Data were analysed by one-, two-or three-way analysis of variance (ANOVA) tests with or without repeated measures, followed by a post-hoc Tukey-Kramer test. The Greenhouse-Geisser's correction was employed when appropriate. A probability was considered to be significant at f5 %. Statistical analyses were performed with SPSS 15.0 (SPSS Inc., USA).
Results
Hyperactivity and immobility induced by acute treatment with quinpirole in C57/Bl6J mice
Mice were injected with QNP (0.1 or 1 mg/kg) or Veh and exposed to the OF for 2 h. Distance travelled was measured in 10 min time intervals. ANOVA showed that the effects of treatment, time interval and the interaction were significant (F Post-hoc tests revealed that mice injected with both doses of QNP travelled significantly shorter distances than Veh-injected mice during the first 50 min (Fig. 1 a) .
In contrast, mice injected with 1 mg/kg QNP travelled a significantly longer distance compared to other groups at 50-80 min (Fig. 1 a) . When locomotion was expressed as a percentage of the distance travelled by Veh-injected mice, the effects of treatment, time interval and the interaction were significant (F 1,18 =5.43, p=0.032 ; F 4.37,78.71 =46.56, p<0.001 ; F 4.37,78.71 =10.34, p<0.001). Post-hoc tests revealed that, during the first 30 min, mice injected with 1 mg/kg QNP displayed a significantly lower percentage of distance travelled than mice injected with 0.1 mg/kg QNP. These data show that both groups had lower levels of locomotion in comparison to the Veh group ( Fig. 1 b) . In contrast, mice injected with 1 mg/kg QNP showed a significantly higher percentage of distance travelled when compared to mice injected with 0.1 mg/kg QNP or Veh at 50-80 min ( Fig. 1 b) . Furthermore, when data were collapsed into 0-50 min and 50-120 min groups, ANOVAs revealed significant differences (F 2,27 = 270.28, p<0.001 ; F 2,27 =19.37, p<0.001). Furthermore, post-hoc tests indicated that during the first 50 min both groups injected with QNP travelled a significantly decreased distance when compared to the Veh group. This effect occurred in a dose-dependent manner ( Fig. 1 c) . From 50 to 120 min, the group injected with the highest dose of QNP displayed a significantly longer distance travelled in comparison with the other groups ( Fig. 1 d) . Regarding immobility time, ANOVA showed that the effects of treatment, time interval and the interaction were significant (F 2,27 =16.54, p<0.001 ; F 3.51,94.80 =6.79, p<0.001 ; F 7.02,94.80 =10.78, p<0.001).
ANOVAs showed that the effect of treatment was significant in the first 50 min and from 60 to 80 min (0-10 min : F 2,27 =461.37, p<0.001 ; 10-20 min : F 2,27 = 377.08, p<0.001 ; 20-30 min : F 2,27 =311.39, p<0.001 ; 30-40 min : F 2,27 =28.94, p<0.001 ; 40-50 min : F 2,27 =21.62, p<0.001 ; 60-70 min : F 2,27 =5.27, p=0.012 ; 70-80 min : F 2,27 =3.79, p=0.036). Post-hoc tests indicated that, during the first 50 min, mice injected with both doses of QNP spent a longer time immobilized compared to the Veh group. This effect also occurred in a dose-dependent manner (Fig. 1 e) . From 60 to 80 min, mice injected with the highest dose of QNP had a similar immobility time compared to the Veh group (Fig. 1 e) . ANOVA performed on collapsed data from 0 to 50 min were significant (F 2,27 =226.48, p<0.001) and post-hoc tests confirmed that both doses of QNP enhanced immobility (Fig. 1 f) . (Fig. 2 a) . When an ANOVA was conducted on the total number of jumps between 70 and 110 min, the effect of treatment was significant (F 3,36 =15.44, p<0.001). Post-hoc tests showed that an injection of 1 mg/kg QNP significantly increased the number of jumps (Fig. 2b) . Concerning rearing behaviour, ANOVA performed between 50 and 90 min indicated that the effect of treatment and the treatmentrtime interval interaction were significant (F 3,36 =4.70, p<0.01 ; F 9,108 =4.83, p<0.001). ANOVAs showed that the effect of treatment was significant in the 60-70 and 70-80 min time intervals (F 3,36 =9.90, p<0.001 ; F 3,36 =10.65, p<0.001). Post-hoc tests revealed that from 60 to 80 min mice injected with 1 mg/kg QNP displayed a significantly higher number of rearing in comparison to the other groups (Fig. 2 c) . ANOVA performed on collapsed data from 60 to 80 min was significant (F 3,36 =15.94, p<0.001). Post-hoc tests showed that an injection of 1 mg/kg QNP significantly increased the number of rearing (Fig. 2 d) . Finally, grooming behaviour was not significantly affected by QNP administration (Fig. 2 e, f) .
FAAH and MAGL inhibitors did not modify locomotion, anxiety, habituation or stereotypic behaviours in C57/Bl6J mice
To evaluate the effects of FAAH and MAGL inhibitors on horizontal locomotion, anxiety and habituation, mice were injected with URB597 (1 mg/kg), URB602 (10 mg/kg) or Veh and tested in two OF sessions with a 24 h inter-session interval. Locomotion was evaluated during the whole duration of the first OF session. ANOVA indicated that neither the effect of treatment (Fig. 3 b) nor the interaction was significant (F 2,33 <1, p=n.s. ; F 10.384,171.34 <1, p=n.s.). However, the effect of time interval was significant (F 5.192,171.34 =7.88, p<0.001). These results suggest that all of the groups showed the same levels of locomotor activity. Furthermore, locomotor activity in the groups progressively decreased in the same manner over time (Fig. 3 a) . To determine if treatment with FAAH and MAGL inhibitors had any effect on anxiety levels and inter-session habituation, we measured the distance travelled by mice in the periphery and the central zone of the OF during the first 30 min of both sessions. A three-way ANOVA, with treatment (Veh or URB597 or URB602) as between-subject factor and zone and day as within-subject factors, indicated that the effect of treatment was not significant (F 2,33 <1, p=n.s.). However, the effects of zone and day were significant (F 1,33 =954.70, p<0.001 ; F 1,33 =59.83, p<0.001). Post-hoc tests showed that all of the groups displayed significantly higher levels of locomotion in the periphery zone of the OF when compared to the central zone (Fig. 3c) . Additionally, during the second OF session, all of the groups showed significantly lower levels of locomotion in comparison to the first session (Fig. 3 d) .
Finally, to study whether FAAH and MAGL inhibitors had any effect on stereotypic behaviours, another subset of mice was injected with URB597 (1 mg/kg), URB602 (10 mg/kg) or Veh and evaluated in the OC over 2 h. We quantified stereotypic behaviours at the specific time intervals where QNP significantly increased locomotion and stereotypic behaviours (Figs. 1 a-f, 2a-f ). ANOVAs showed that neither group differed in the number of jumping, rearing or grooming behaviours (F 2,27 <1, p=n.s. ; F 2,27 =1.64, p=n.s. ; F 2,27 <1, p=n.s.) (Fig. 3 e-g ). These results lead us to conclude that treatment with FAAH or MAGL inhibitors did not modify locomotor activity, anxiety, habituation or stereotypic behaviours in C57/Bl6J mice.
Co-administration of FAAH or MAGL inhibitors and quinpirole counteracts quinpirole-induced hyperactivity and stereotypic behaviour
Groups of mice were injected with Veh, QNP (1 mg/kg), QNP and URB597 (1 mg/kg) or QNP and URB602 (10 mg/kg) and evaluated in the OF and OC. In the first 50-70 min post-injection, FAAH and MAGL inhibitors did not reverse nor potentiate the motor depressing effects of QNP (distance travelled in the OF in the first 50 min : F 3,44 =140.76, p<0.001 ; rearing in the OC in the first 60 min : F 3,44 =30.51, p<0.001) (Fig. 4 a, c) . Number of jumps did not differ at this early phase of QNP action (F 3,44 <1, p=n.s. ; Fig. 4 b) . However, inhibition of endocannabinoid degradation did suppress the enhanced locomotion and stereotypic activity that appears in the second phase of QNP action (distance travelled in the OF : F 3,44 =15.71, p<0.001 ; jumps and rearing in the OC : F 3,44 =13.98, p<0.001 ; F 3,44 =10.46, p<0.001 ; Fig. 4 d-f ). Post-hoc tests confirmed that mice injected with QNP travelled a longer distance and displayed a higher number of jumps and rearing in comparison to the other groups (Fig. 4 d-f) . Furthermore, groups injected with QNP+URB597 or QNP+URB602 did not differ from Veh-injected mice. These results suggest that coadministration of FAAH or MAGL inhibitors with QNP reversed QNP-induced hyperactivity and stereotypic behaviours.
Effects of FAAH and MAGL inhibitors on cocaine-induced locomotion and behavioural sensitization
We conducted a series of experiments to study the influence of FAAH and MAGL inhibitors on : (a) the locomotion response elicited by acute cocaine administration ; (b) the acquisition of cocaine-induced sensitization ; (c) the expression of conditioned locomotion ; (d) the expression of cocaine sensitization. In an initial experiment, a group of mice were injected with a single dose of cocaine (20 mg/kg), URB597 (1 mg/kg), URB602 (10 mg/kg), Veh or cocaine with URB597 or URB602. ANOVA indicated that the effect of treatment was significant (F 5,42 =39.10, p<0.001). Post-hoc tests showed that the distance travelled by mice injected with cocaine alone or injected with cocaine and URB597 or URB602 was significantly longer in comparison to the groups injected with Veh, URB597 or URB602 (Fig. 5 a) . This result suggests that FAAH and MAGL inhibitors did not affect the acute cocaineinduced locomotion response. In a second experiment, another cohort of animals were injected once per day for five consecutive days with cocaine (20 mg/kg), URB597 (1 mg/kg), URB602 (10 mg/kg), Veh or cocaine with URB597 or URB602. ANOVA showed that the effects of treatment, day and the interaction were significant (F 5,54 =63.72, p<0.001 ; F 3.06,165.30 =31.36, p<0.001 ; F 15.30,165.30 =3.38, p<0.001) . ANOVAs performed on each day were also all significant (day 1 : F 5,54 =11.30, p<0.001 ; day 2 : F 5,54 = 56.91, p<0.001 ; day 3 : F 5,54 =31.88, p<0.001 ; day 4 : F 5,54 =25.21, p<0.001 ; day 5 : F 5,54 =41.07, p<0.001). Post-hoc tests revealed that the distance travelled by mice injected with cocaine alone or injected with URB597 or URB602 and cocaine was significantly longer than distance travelled by mice injected with URB597, URB602 or Veh (Fig. 5 b) . This result suggests that the endocannabinoid degradation inhibitors did not produce any effect on cocaine Pavlovian conditioning. Next, mice were left undisturbed for five consecutive days. Twenty-four hours later, groups previously conditioned with cocaine were injected with Veh and exposed to the OF to evaluate the conditioned locomotion response. The next day, mice in the same groups were injected with a prime dose of cocaine (10 mg/kg). Cocaine sensitization was evaluated by comparing the distance travelled by the mice after injection of the prime dose of cocaine to the distance travelled on the previous day (conditioned locomotion). The ANOVA indicated that the effects of pretreatment (cocaine, cocaine+URB597 or cocaine+URB602) and the pretreatmentrprotocol interaction (conditioned locomotion or cocaine sensitization) were not significant (F 2,27 <1 in both cases). In contrast, the effect of the protocol was significant (F 1,27 =121,02, p<0.001). Post-hoc tests showed that the three groups travelled significantly longer distances during the cocaine sensitization session when compared to the conditioned locomotion session (Fig. 5 c) . These results suggest that administration of FAAH and MAGL inhibitors during cocaine conditioning did not affect the development of conditioned locomotion and cocaine sensitization.
Additionally, we conducted another experiment to study the effects of acute administration of FAAH and MAGL inhibitors on the conditioned locomotion and cocaine sensitization response. Mice were conditioned with cocaine (20 mg/kg) or treated with Veh over five consecutive days (data not shown). Five days after finishing the conditioning protocol, a subset of mice were treated with Veh, URB597 (1 mg/kg) or URB602 (10 mg/kg) and exposed to the OF. ANOVA (F 3,36 =8.07, p<0.001) followed by post-hoc tests indicated that mice conditioned with cocaine travelled a significantly longer distance when compared to mice previously treated with Veh (Fig. 5 d) . Moreover, mice previously conditioned with cocaine and treated with an acute injection of URB597 or URB602 also travelled a significantly longer distance than mice previously treated with Veh (Fig. 5d ). This suggests that acute treatment with endocannabinoid degradation inhibitors did not modify the conditioned locomotion response. Finally, another subset of animals previously conditioned with cocaine received a prime injection of cocaine (10 mg/kg) with or without an acute injection of URB597 or URB602. Mice previously treated with Veh received an acute injection of cocaine or Veh. ANOVA (F 4,45 =24.93, p<0.001) followed by post-hoc tests revealed that mice that received acute administration of the MAGL inhibitor (URB602) did not develop the sensitization response (Fig. 5 e) .
Discussion
Growing evidence has established that the ECS acts as a modulator of dopamine transmission in the basal ganglia (Giuffrida & Piomelli, 2000 ; Rodriguez de Fonseca et al. 1998) . The development of endocannabinoid degradation inhibitors has opened up new alternatives for developing endocannabinoidbased therapeutic strategies in dopamine-related disorders (Fernández-Espejo et al. 2009 ; Piomelli, 2003) . To illustrate the effects of these inhibitors on dopamine-mediated behaviours, we characterized the behavioural performance of mice treated with QNP. After QNP treatment, we subsequently studied pharmacological effects of endocannabinoid degradation inhibitors on either QNP-or cocaine-induced behaviours. Results demonstrated the following : (1) similar to rats, QNP produced a biphasic locomotion response in mice (depression of locomotion followed by a marked activation) and a dose-dependent increase in stereotyped behaviours ; (2) inhibition of either FAAH or MAGL abolished the increase in locomotion induced by a high dose of QNP and suppressed the induction of stereotyped behaviours ; finally, (3) inhibition of both FAAH and MAGL affected neither psychomotor actions of cocaine nor the acquisition of sensitization. However, blockage of 2-AG degradation did reduce the expression of an already acquired cocaine-induced sensitization. These results indicate that inhibition of endocannabinoid degradation exerts a potent suppression of dopamine D 2 /D 3 receptormediated stimulatory effects on behaviour. However, a very limited suppression of the maximal psychostimulant effects of cocaine was observed. Activation of the dopamine D 2 /D 3 receptor produces a marked decrease in motor activity by inhibiting dopamine release from dopaminergic terminals projecting to the basal ganglia. This effect is mediated through presynaptic dopamine D 2 /D 3 receptors (Davis et al. 1997) . Despite this inhibitory effect, stimulation of post-synaptic dopamine D 2 /D 3 receptors produces enhanced locomotion and characteristic stereotyped behaviours (including jumping, climbing and oral movements). Thus, in rats a high dose of QNP produces a typical inhibitory component in behaviour, followed by a temporary activation of locomotion and stereotypies (Eilam et al. 1992 ; Rodriguez de Fonseca et al. 1994) . We characterized this response in C57Bl/6J mice and found similar pharmacological effects, which have also been recently described (de Haas et al. in press ; Jung & Shim, 2011) . As depicted in Fig. 1 , the highest dose of QNP produced stimulation of movement after its initial depressor effect. The activation of behaviour induced by QNP was transient and it was accompanied by characteristic jumping and rearing behaviours, but not grooming (a dopamine D 1 -mediated behaviour ; Starr & Starr, 1986) as depicted in Fig. 2 . On the basis of these results, we selected a dose of 1 mg/kg QNP to analyse the actions of the endocannabinoid degradation inhibitors. These inhibitors were used at doses that did not result in motor depressant effects but are known to fully inhibit enzymatic activity ( Fig. 3 ; Hohmann et al. 2005 ; Kathuria et al. 2003 ; Luchicchi et al. 2010) . When these inhibitors were injected prior to QNP, its inhibitory effect on behavioural output was not affected. This can be expected because dopamine neuron terminals (which release dopamine) lack cannabinoid CB 1 receptors (Martin et al. 2008) . However, pharmacological inhibition of either FAAH or MAGL induced an attenuation of behavioural stimulation elicited by QNP. This attenuation indicates that the increase in AEA and 2-AG is sufficient to abolish the stimulatory component derived from dopamine D 2 /D 3 receptor activation. Similar findings have been described for AEA transport inhibitor AM404 (Beltramo et al. 2000) . This finding might have important consequences for therapeutics, particularly in Parkinson's disease and schizophrenia. For example, dyskinesia and stereotyped behaviours associated with repeated stimulation of dopamine D 2 receptors appear after long-term treatment with L-DOPA or dopamine agonists in Parkinson's disease or in the context of psychostimulant abuse (Ferrer et al. 2003 (Ferrer et al. , 2007 Gorriti et al. 1999) . In both cases, stimulation of cannabinoid CB 1 receptors reduced their presence in animal models (Ferrer et al. 2003 (Ferrer et al. , 2007 Gorriti et al. 1999) . Regarding schizophrenia, positive symptoms (i.e. delusion, hallucination or behavioural disorganization) depend on activation of dopamine D 2 receptors and are inversely correlated with cerebrospinal fluid AEA (Giuffrida et al. 2004) . Hypothetically, an increase in brain endocannabinoids resulting from pharmacological inhibition of FAAH and/or MAGL might attenuate these symptoms.
Mechanistically, these effects on dopamine D 2 /D 3 receptor-mediated responses can be attributed to endocannabinoids released through activation of D 2 /D 3 receptors. Either AEA or 2-AG (released after dopamine receptor activation) might act in several places across the basal ganglia circuitry by engaging cannabinoid CB 1 receptors to reduce dopamine-induced behavioural activation. For instance, endocannabinoids can control pre-synaptic dopamine release (O'Neill et al. 2009 ). This effect most likely occurs through transsynaptic actions because cannabinoid CB 1 receptors are not present in dopaminergic neurons (Martin et al. 2008) . Additionally, endocannabinoids can regulate dopamine receptor-mediated transmission. Cannabinoid CB 1 receptors are co-expressed with either dopamine D 1 or D 2 /D 3 receptors in medium spiny striatal neurons. Endocannabinoids can regulate signalling at these receptors, most likely through interaction with CB 1 receptor dimers (formed with dopamine D 2 /D 3 receptors or adenosine A 2A receptors (Navarro et al. 2008) ) or by regulating dopamine D 2 /D 3 receptor availability (Crunelle et al. 2011) . Finally, endocannabinoids can exert their effects by regulating corticostriatal glutamatergic transmission (similar to dopamine), therefore regulating dopamine-mediated modulation of synaptic plasticity within the basal ganglia (Adermark & Lovinger, 2007 ; Adermark et al. 2009 ; Gerdeman & Lovinger, 2001) .
In the present study, we did not find any effects of endocannabinoid degradation inhibitors on psychostimulant effects of cocaine (Fig. 5) . Although the role of endogenous cannabinoids as modulators of dopamine transmission in addiction is clearly established (Colombo et al. 2005 ; Ledent et al. 1999 ; Maldonado & Rodriguez de Fonseca, 2002 ; Scherma et al. 2008 ; Solinas et al. 2007 Solinas et al. , 2008 , there is not a general consensus about the functions of the ECS in cocaine addiction (Arnold, 2005) . Some studies indicate that neither pharmacological antagonism nor deletion of the CB 1 receptor alters the acute rewarding effects of cocaine (Adamczyk et al. 2012 ; Lesscher et al. 2005 ; Orio et al. 2009 ). However, there are other studies that show the contrary (Li et al. 2009 ; Soria et al. 2005 ; Xi et al. 2008) . CB 1 receptors appear to be involved in the association of cocaine reward with environmental cues, reinstatement of cocaine self-administration and acquisition of behavioural sensitization (Adamczyk et al. 2012 ; de Vries et al. 2001 ; Gerdeman et al. 2008) . Additionally, a new role for cannabinoid CB 2 receptors in cocaine addiction is emerging (Xi et al. 2011) . In the present study, inhibition of FAAH or MAGL affected neither acute psychomotor actions of cocaine nor the acquisition of behavioural sensitization or the expression of conditioned locomotion. Because cocaine is not a selective blocker of dopamine uptake, we can hypothesize that the psychostimulant profile of cocaine may be independent of endocannabinoid modulation of dopaminergic transmission. In this sense, it is important to note that the effects of cocaine on serotonin transporters are sufficient to sustain the rewarding effects of the psychostimulant in dopamine-deficient mice (Hnasko et al. 2007) . Thus, it is feasible to hypothesize that an increase in endocannabinoid availability by inhibiting endocannabinoid degradation may not be sufficient to attenuate psychostimulant actions of cocaine.
Finally, we observed a MAGL-induced decrease in the expression of an already acquired cocaine-induced sensitization. Because sensitization involves effects of external associative cues, this pharmacological effect could be associated with those described for other ECSdependent associative responses in Pavlovian conditioning protocols with cocaine (Adamczyk et al. 2012 ; de Vries et al ; Gerdeman et al. 2008) . However, the specificity of our observation, together with the lack of effects of endocannabinoid degradation inhibitors on conditioned locomotion, makes it very difficult to draw conclusions about the role of this class of drugs in Pavlovian conditioning. Whether this selective attenuation of behavioural sensitization reflects a state-dependent change in dopamine transmission induced by cocaine (Chefer & Shippenberg, 2002) , differential adaptations in 2-AG signalling or 2-AG selective actions on striatal plasticity associated with repeated cocaine exposure remains to be determined.
In summary, the present study demonstrates that inhibition of endocannabinoid degradation attenuates dopamine D 2 /D 3 receptor-mediated behavioural activation. This finding might be relevant for neuropsychopharmacological therapies for dopaminerelated disorders.
